Comparative Pharmacology
Head-to-head clinical analysis: ACTONEL WITH CALCIUM COPACKAGED versus DIDRONEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTONEL WITH CALCIUM COPACKAGED versus DIDRONEL.
ACTONEL WITH CALCIUM (COPACKAGED) vs DIDRONEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTONEL WITH CALCIUM (COPACKAGED) contains risedronate sodium, a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway. This leads to reduced bone turnover and increased bone mineral density. The calcium component is for supplementation to prevent hypocalcemia.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone, reducing osteoclast activity and inducing osteoclast apoptosis.
Actonel (risedronate) 35 mg orally once weekly, taken with 6-8 oz of plain water at least 30 minutes before breakfast. Calcium supplement (e.g., 1250 mg calcium carbonate) taken with food at a different time of day.
For Paget disease: 5 mg/kg orally once daily for 6 months, or 5 mg/kg orally once daily for 3 months if retreatment; for heterotopic ossification: 20 mg/kg orally once daily for 2 weeks pre- and 3 months post-surgery; for hypercalcemia of malignancy: 5-10 mg/kg orally once daily for up to 6 months.
None Documented
None Documented
Terminal elimination half-life of risedronate is approximately 20 hours for the 5 mg daily dose and 480 hours for the 35 mg weekly dose due to prolonged retention in bone; clinically, the drug accumulates in bone and is slowly released.
Terminal elimination half-life ranges from hours to weeks; initial phase 2-6 hours, deep bone phase up to several weeks due to slow release from bone.
Risedronate is eliminated primarily via renal excretion, with approximately 50% of an absorbed dose excreted unchanged in urine. Unabsorbed drug is eliminated in feces. Total clearance is about 100 mL/min.
Renal: 50% unchanged; fecal/biliary: negligible; absorbed drug not excreted renally is retained in bone with slow release.
Category C
Category C
Bisphosphonate and Calcium Supplement
Bisphosphonate